^
    1d
    INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM) (clinicaltrials.gov)
    P1/2, N=52, Active, not recruiting, Inovio Pharmaceuticals | Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Dec 2024
    Trial completion date • Trial primary completion date • Combination therapy
    |
    temozolomide • Libtayo (cemiplimab-rwlc) • INO-5401 • rocakinogene sifuplasmid (INO-9012)
    18d
    INO-5401 + INO-9012 in Combination With Atezolizumab in Locally Advanced Unresectable or Metastatic/Recurrent Urothelial Carcinoma (clinicaltrials.gov)
    P1/2, N=35, Active, not recruiting, Inovio Pharmaceuticals | Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Dec 2024
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    Tecentriq (atezolizumab) • INO-5401 • rocakinogene sifuplasmid (INO-9012)
    29d
    A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=47, Terminated, Sumitomo Pharma America, Inc. | Phase classification: P1b/2 --> P1/2 | Completed --> Terminated; Sponsor's decision to terminate development of the program.
    Phase classification • Trial termination • Combination therapy • Checkpoint inhibition • Metastases
    |
    MSI (Microsatellite instability) • HLA-A (Major Histocompatibility Complex, Class I, A) • HLA-B (Major Histocompatibility Complex, Class I, B)
    |
    MSI-H/dMMR • HLA-A*02 • HLA-A*24
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • adegramotide/nelatimotide (DSP-7888)
    2ms
    SLSG18-301: Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2 (clinicaltrials.gov)
    P3, N=126, Active, not recruiting, Sellas Life Sciences Group | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Venclexta (venetoclax) • cytarabine • azacitidine • decitabine • Zeltherva (galinpepimut-S) • hydroxyurea • Leukine (sargramostim)
    3ms
    Study of ASP7517 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors Expressing WT1 Antigen (clinicaltrials.gov)
    P1/2, N=24, Active, not recruiting, Astellas Pharma Global Development, Inc. | Trial completion date: Dec 2027 --> Jun 2024 | Trial primary completion date: Dec 2027 --> Jun 2024
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    EGFR (Epidermal growth factor receptor) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • WT1 (WT1 Transcription Factor)
    |
    EGFR mutation • ALK positive • ALK mutation
    |
    Keytruda (pembrolizumab) • ASP7517
    4ms
    Antigen-specific T Cell Therapy for AML or MDS Patients With Relapsed Disease After Allo-HCT (clinicaltrials.gov)
    P1/2, N=22, Active, not recruiting, NexImmune Inc. | Recruiting --> Active, not recruiting | Trial completion date: Mar 2023 --> Mar 2025 | Trial primary completion date: Oct 2022 --> Oct 2024
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    HLA-A (Major Histocompatibility Complex, Class I, A) • HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • HLA-DQB1 (Major Histocompatibility Complex, Class II, DQ Beta 1) • HLA-B (Major Histocompatibility Complex, Class I, B) • HLA-C (Major Histocompatibility Complex, Class I, C)
    |
    cyclophosphamide • NEXI-001
    4ms
    Dose Escalation Trial of WT1-specific Donor-derived T Cells Following T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov)
    P1, N=29, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Dec 2024
    Trial completion date • Trial primary completion date
    |
    HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • HLA-DQB1 (Major Histocompatibility Complex, Class II, DQ Beta 1)
    |
    melphalan • fludarabine IV • busulfan • ATA520
    5ms
    WP42004: A Dose Escalation and Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7283420. (clinicaltrials.gov)
    P1, N=59, Completed, Hoffmann-La Roche | Recruiting --> Completed | N=220 --> 59 | Trial completion date: Feb 2026 --> Aug 2023 | Trial primary completion date: Feb 2026 --> Aug 2023
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date
    |
    HLA-A (Major Histocompatibility Complex, Class I, A)
    |
    HLA-A*02
    |
    dasatinib • Actemra IV (tocilizumab) • RG6007 • dexamethasone injection
    7ms
    Dose Escalation of HLA-A2-WT1 CD3 T-Cell Bispecific Antibody in a Phase I Study in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) (ASH 2023)
    RO7283420 is the first TCR-L TCB antibody evaluated in AML. We observed pharmacodynamic evidence of T-cell activation and expansion in the clinic, in line with the expected MoA of TCBs, however, at the explored doses, no clear exposure-response relationship and only a modest clinical activity were observed. The safety profile was shown to be consistent with the other TCBs and R/R AML population.
    Clinical • P1 data
    |
    TP53 (Tumor protein P53) • FLT3 (Fms-related tyrosine kinase 3) • NPM1 (Nucleophosmin 1) • CD8 (cluster of differentiation 8) • HLA-A (Major Histocompatibility Complex, Class I, A) • RUNX1 (RUNX Family Transcription Factor 1) • ASXL1 (ASXL Transcriptional Regulator 1) • WT1 (WT1 Transcription Factor)
    |
    HLA-A*02
    |
    RG6007
    7ms
    Study of 3D189 in Patients With Hematologic Malignancies (clinicaltrials.gov)
    P1, N=15, Active, not recruiting, 3D Medicines | Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2023 --> May 2024
    Enrollment closed • Trial primary completion date
    |
    WT1 (WT1 Transcription Factor)
    |
    WT1 expression • WT1 positive
    |
    Zeltherva (galinpepimut-S)
    7ms
    PHASE 1/2 STUDY OF GALINPEPIMUT-S PLUS PEMBROLIZUMAB COMBINATION IN PATIENTS WITH WT1+ PLATINUM-RESISTANT OVARIAN CANCER IN 2ND/3RD LINE OF THERAPY (IGCS 2023)
    Safety: N=25, GPS alone=8 (due to disease progression); >1 dose of combination =17. Median age: 64-yrs; median number of prior lines: 2. Five patients experienced 11 SAEs, one of which was drug related.
    Clinical • P1/2 data
    |
    CD8 (cluster of differentiation 8) • WT1 (WT1 Transcription Factor) • CD4 (CD4 Molecule) • CSF2 (Colony stimulating factor 2)
    |
    Keytruda (pembrolizumab) • Zeltherva (galinpepimut-S)
    9ms
    WT1 and PRAME RNA-loaded dendritic cell vaccine as maintenance therapy in de novo AML after intensive induction chemotherapy. (PubMed, Leukemia)
    Oral azacytidine may be used as maintenance treatment in AML in first remission, but can be associated with substantial side effects, and less toxic strategies should be explored. OS at five years was 75% (95% CI: 50-89), with 70% of patients ≥60 years of age being long-term survivors. Maintenance therapy with this DC vaccine was well tolerated in AML patients in CR1 and was accompanied by encouraging 5-year long-term survival.
    Journal
    |
    PRAME (Preferentially Expressed Antigen In Melanoma)
    |
    azacitidine • CVT-DC-01 • DC vaccine for prostate cancer
    9ms
    A Dose Escalation and Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7283420. (clinicaltrials.gov)
    P1, N=220, Recruiting, Hoffmann-La Roche | Suspended --> Recruiting
    Enrollment open
    |
    HLA-A (Major Histocompatibility Complex, Class I, A)
    |
    HLA-A*02
    |
    dasatinib • Actemra IV (tocilizumab) • RG6007 • dexamethasone injection
    10ms
    Using a Targeted Cancer Vaccine (Galinpepimut-S) With Immunotherapy (Nivolumab) in Mesothelioma (clinicaltrials.gov)
    P1, N=10, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Jul 2023 --> Jul 2024 | Trial primary completion date: Jul 2023 --> Jul 2024
    Trial completion date • Trial primary completion date • Checkpoint inhibition
    |
    WT1 (WT1 Transcription Factor)
    |
    Opdivo (nivolumab) • Zeltherva (galinpepimut-S) • Leukine (sargramostim)
    11ms
    Study of Mana 312 (Multi Tumor-Associated Antigen T Cells) in Adults With AML/MDS After HSCT (clinicaltrials.gov)
    P1, N=11, Terminated, Mana Therapeutics | N=27 --> 11 | Active, not recruiting --> Terminated; Product manufacturing
    Enrollment change • Trial termination
    |
    MANA-312
    11ms
    A Study Investigating the Safety, Tolerability and Efficacy of ASP7517 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML) and Relapsed/Refractory Higher Risk Myelodysplastic Syndrome (MDS) (clinicaltrials.gov)
    P1/2, N=43, Completed, Astellas Pharma Global Development, Inc. | Active, not recruiting --> Completed | Trial completion date: Feb 2024 --> Jun 2023 | Trial primary completion date: Feb 2024 --> Jun 2023
    Trial completion • Trial completion date • Trial primary completion date
    |
    ASP7517
    1year
    An analysis of a first-in-human study of NEXI-001 donor-derived antigen-specific CD8+ T-cell treatment of relapsed AML after allogeneic hematopoietic cell transplantation (HCT). (ASCO 2023)
    Early results indicate that the antigen-specific NEXI-001 T cells have the potential to enhance GvL effects and is tolerated with easily manageable side effects. Greater clinical activity has been observed with increased doses of the NEXI-001 T cells. The trial remains ongoing, and the data support an Expansion Cohort of the study that will allow for a more complete assessment of clinical activity.
    P1 data
    |
    CD8 (cluster of differentiation 8) • WT1 (WT1 Transcription Factor) • CD4 (CD4 Molecule) • PRAME (Preferentially Expressed Antigen In Melanoma) • CCNA1 (Cyclin A1)
    |
    NEXI-001
    1year
    A Dose Escalation and Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7283420. (clinicaltrials.gov)
    P1, N=220, Suspended, Hoffmann-La Roche | Recruiting --> Suspended
    Trial suspension
    |
    HLA-A (Major Histocompatibility Complex, Class I, A)
    |
    HLA-A*02
    |
    dasatinib • Actemra IV (tocilizumab) • RG6007 • dexamethasone injection
    1year
    The Essential Glucose Transporter GLUT1 is Epigenetically Upregulated by C/EBPb and WT1 During Decidualization of Human Endometrial Stromal Cells. (SRI 2023)
    Glucose uptake was examined by 2-deoxyglucose uptake assay... GLUT1 is involved in the increase of glucose uptake in ESCs during decidualization. The up-regulation of GLUT1 is mediated by the promoter bindings of C/EBPβ and WT1. Furthermore, both C/EBPβ and WT1 contribute to induce the epigenetic changes of the GLUT1 promoter by recruiting p300.
    Stroma
    |
    WT1 (WT1 Transcription Factor) • IGFBP1 (Insulin Like Growth Factor Binding Protein 1) • SLC2A1 (Solute Carrier Family 2 Member 1)
    1year
    Targeting leukemic stem cell subpopulation in AML using phytochemicals: An in-silico and in-vitro approach. (PubMed, Comput Biol Med)
    The results revealed Gallic acid (GA) and Chlorogenic acid (CA) as promising WT1 inhibitors...We found that GA significantly downregulated both these genes compared to CA. Our results suggested that GA is a potential inhibitor of WT1 and might be an excellent anti-LSCs natural drug for AML patients.
    Preclinical • Journal • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • WT1 (WT1 Transcription Factor)
    |
    BCL2 expression
    |
    chlorogenic acid
    1year
    Study of ASP7517 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors Expressing WT1 Antigen (clinicaltrials.gov)
    P1/2, N=24, Active, not recruiting, Astellas Pharma Global Development, Inc. | N=385 --> 24
    Enrollment change • Combination therapy • Metastases
    |
    EGFR (Epidermal growth factor receptor) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • WT1 (WT1 Transcription Factor)
    |
    EGFR mutation • ALK positive • ALK mutation
    |
    Keytruda (pembrolizumab) • ASP7517
    1year
    Phase I Study of a Multivalent WT1 Peptide Vaccine (Galinpepimut-S) in Combination with Nivolumab in Patients with WT1-Expressing Ovarian Cancer in Second or Third Remission. (PubMed, Cancers (Basel))
    Therapy included six (every two weeks) subcutaneous inoculations of galinpepimut-S vaccine adjuvanted with Montanide, low-dose subcutaneous sargramostim at the injection site, with intravenous nivolumab over 12 weeks, and up to six additional doses until disease progression or toxicity. Coadministration of galinpepimut-S and nivolumab demonstrated a tolerable toxicity profile and induced immune responses, as indicated by immunophenotyping and WT1-specific IgG production. Exploratory analysis for efficacy yielded a promising 1-year PFS rate.
    P1 data • Journal • Combination therapy
    |
    WT1 (WT1 Transcription Factor)
    |
    Opdivo (nivolumab) • Zeltherva (galinpepimut-S) • Leukine (sargramostim)
    over1year
    WIZARD201G: A Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy (clinicaltrials.gov)
    P3, N=221, Completed, Sumitomo Pharma Oncology, Inc. | Active, not recruiting --> Completed
    Trial completion • Combination therapy
    |
    MGMT (6-O-methylguanine-DNA methyltransferase) • HLA-A (Major Histocompatibility Complex, Class I, A)
    |
    HLA-A*02 • HLA-A*24:02
    |
    Avastin (bevacizumab) • adegramotide/nelatimotide (DSP-7888)
    over1year
    Study of ASP7517 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors Expressing WT1 Antigen (clinicaltrials.gov)
    P1/2, N=385, Active, not recruiting, Astellas Pharma Global Development, Inc. | Recruiting --> Active, not recruiting
    Enrollment closed • Combination therapy • Metastases
    |
    EGFR (Epidermal growth factor receptor) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • WT1 (WT1 Transcription Factor)
    |
    EGFR mutation • ALK positive • ALK mutation
    |
    Keytruda (pembrolizumab) • ASP7517
    over1year
    Dose Escalation Trial of WT1-specific Donor-derived T Cells Following T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov)
    P1, N=29, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Dec 2022 --> Dec 2023 | Trial primary completion date: Dec 2022 --> Dec 2023
    Trial completion date • Trial primary completion date
    |
    HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • HLA-DQB1 (Major Histocompatibility Complex, Class II, DQ Beta 1)
    |
    melphalan • fludarabine IV • busulfan • ATA520
    over1year
    Shikonin as a WT1 Inhibitor Promotes Promyeloid Leukemia Cell Differentiation. (PubMed, Molecules)
    shikonin can down-regulate the WT1 protein level for leukemia differentiation therapy, and 2. the interaction between WT1 and CD34 proteins may be responsible for granulocyte/monocyte immaturity in HL-60 cells.
    Journal
    |
    WT1 (WT1 Transcription Factor) • CD34 (CD34 molecule) • ITGAM (Integrin, alpha M)
    |
    WT1 overexpression
    over1year
    A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1b/2, N=47, Completed, Sumitomo Pharma Oncology, Inc. | Active, not recruiting --> Completed | N=84 --> 47
    Trial completion • Enrollment change • Combination therapy • Checkpoint inhibition • Metastases
    |
    MSI (Microsatellite instability) • HLA-A (Major Histocompatibility Complex, Class I, A) • HLA-B (Major Histocompatibility Complex, Class I, B)
    |
    MSI-H/dMMR • HLA-A*02
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • adegramotide/nelatimotide (DSP-7888)
    over1year
    Using a Targeted Cancer Vaccine (Galinpepimut-S) With Immunotherapy (Nivolumab) in Mesothelioma (clinicaltrials.gov)
    P1, N=10, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Recruiting --> Active, not recruiting
    Enrollment closed • Checkpoint inhibition
    |
    WT1 (WT1 Transcription Factor)
    |
    Opdivo (nivolumab) • Zeltherva (galinpepimut-S) • Leukine (sargramostim)
    over1year
    A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1b/2, N=84, Active, not recruiting, Sumitomo Pharma Oncology, Inc. | Trial completion date: Feb 2024 --> Nov 2022 | Trial primary completion date: Aug 2023 --> Oct 2022
    Trial completion date • Trial primary completion date • Combination therapy • Checkpoint inhibition • Metastases
    |
    MSI (Microsatellite instability) • HLA-A (Major Histocompatibility Complex, Class I, A) • HLA-B (Major Histocompatibility Complex, Class I, B)
    |
    MSI-H/dMMR • HLA-A*02
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • adegramotide/nelatimotide (DSP-7888)
    over1year
    A Dose Escalation and Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7283420. (clinicaltrials.gov)
    P1, N=220, Recruiting, Hoffmann-La Roche | Trial completion date: Oct 2024 --> Feb 2026 | Trial primary completion date: Oct 2024 --> Feb 2026
    Trial completion date • Trial primary completion date
    |
    HLA-A (Major Histocompatibility Complex, Class I, A)
    |
    HLA-A*02
    |
    dasatinib • Actemra IV (tocilizumab) • RG6007 • dexamethasone injection
    over1year
    Initial Characterization of Nexi-001, a Donor-Derived T-Cell Product, for the Treatment AML Patients That Have Relapsed after Allogeneic Hematopoietic Stem Cell Transplant (ASH 2022)
    In summary, we have developed a novel AIM np-based T cell expansion platform for the rapid, streamlined generation of clinically relevant number of tumor-specific, multi-antigen, memory CD8+ T cells in 14 days. The results reported here support the development of additional multi-institution phase 1 /2 clinical trials of adoptive T cell transfer in hematologic and solid cancers.
    Clinical
    |
    CD8 (cluster of differentiation 8) • WT1 (WT1 Transcription Factor) • PRAME (Preferentially Expressed Antigen In Melanoma) • CCNA1 (Cyclin A1)
    |
    NEXI-001
    over1year
    Study Investigating NTLA-5001 in Subjects With Acute Myeloid Leukemia (clinicaltrials.gov)
    P1/2, N=6, Terminated, Intellia Therapeutics | N=54 --> 6 | Trial completion date: Sep 2025 --> Aug 2022 | Active, not recruiting --> Terminated | Trial primary completion date: Nov 2023 --> Jul 2022; Pivoting to an allogeneic version of this program currently in preclinical development.
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    |
    HLA-A (Major Histocompatibility Complex, Class I, A)
    |
    HLA-A*02
    |
    cyclophosphamide • Allo WT1-TCR
    over1year
    INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM) (clinicaltrials.gov)
    P1/2, N=52, Active, not recruiting, Inovio Pharmaceuticals | Trial completion date: Dec 2022 --> Dec 2023 | Trial primary completion date: Dec 2022 --> Dec 2023
    Trial completion date • Trial primary completion date • Combination therapy
    |
    IFNG (Interferon, gamma)
    |
    temozolomide • Libtayo (cemiplimab-rwlc) • INO-5401 • rocakinogene sifuplasmid (INO-9012)
    over1year
    Mechanism of action of DSP-7888 (adegramotide/nelatimotide) Emulsion, a peptide-based therapeutic cancer vaccine with the potential to turn up the heat on non-immunoreactive tumors. (PubMed, Clin Transl Oncol)
    DSP-7888 Emulsion can promote both cytotoxic and helper T-cell-mediated immune responses against WT1-positive tumors. Adegramotide enhances CTL numbers, and the CTLs induced by treatment with both nelatimotide and adegramotide are capable of functioning within the immunosuppressive tumor microenvironment. The ability of anti-PD-1 to enhance the antitumor activity of DSP-7888 Emulsion in mice implanted with WT1-positive tumors suggests the potential for synergy.
    Journal
    |
    CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • WT1 (WT1 Transcription Factor) • CD4 (CD4 Molecule)
    |
    WT1 expression • WT1 positive
    |
    adegramotide/nelatimotide (DSP-7888)
    over1year
    A Dose Escalation and Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7283420. (clinicaltrials.gov)
    P1, N=220, Recruiting, Hoffmann-La Roche | N=160 --> 220
    Enrollment change
    |
    HLA-A (Major Histocompatibility Complex, Class I, A)
    |
    HLA-A*02
    |
    dasatinib • Actemra IV (tocilizumab) • RG6007 • dexamethasone injection
    over1year
    Study of 3D189 in Patients With Hematologic Malignancies (clinicaltrials.gov)
    P1, N=15, Recruiting, 3D Medicines | Not yet recruiting --> Recruiting | Trial completion date: Jun 2024 --> Dec 2024
    Enrollment open • Trial completion date
    |
    WT1 (WT1 Transcription Factor)
    |
    WT1 expression • WT1 positive
    |
    Zeltherva (galinpepimut-S)
    almost2years
    Study Investigating NTLA-5001 in Subjects With Acute Myeloid Leukemia (clinicaltrials.gov)
    P1/2, N=54, Active, not recruiting, Intellia Therapeutics | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    HLA-A (Major Histocompatibility Complex, Class I, A)
    |
    HLA-A*02
    |
    cyclophosphamide • Allo WT1-TCR
    almost2years
    Lurbinectedin inhibits the EWS-WT1 transcription factor in desmoplastic small round cell tumor. (PubMed, Mol Cancer Ther)
    This provides evidence for a "class effect" for the more than 18 tumors driven by EWSR1 fusion proteins. More importantly, the data establishes lurbinectedin as a promising clinical candidate for DSRCT.
    Journal
    |
    WT1 (WT1 Transcription Factor) • EWSR1 (EWS RNA Binding Protein 1) • FLI1 (Fli-1 Proto-Oncogene ETS Transcription Factor)
    |
    Zepzelca (lurbinectedin)
    almost2years
    WT1 Inhibits Human Renal Carcinoma Cell Proliferation and Induces G2/M Arrest by Upregulating IL-24 Expression. (PubMed, Biomed Res Int)
    Our results demonstrated that the overexpression of WT1 upregulates IL-24, leading to G2/M checkpoint arrest to reduce proliferation. These results indicate that regulation of IL-24 by WT1 inhibits proliferation and may represent a potential target for treating renal carcinoma.
    Journal
    |
    WT1 (WT1 Transcription Factor) • TXNIP (Thioredoxin Interacting Protein)
    |
    WT1 overexpression
    almost2years
    INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM) (clinicaltrials.gov)
    P1/2, N=52, Active, not recruiting, Inovio Pharmaceuticals | Trial completion date: Jun 2022 --> Dec 2022 | Trial primary completion date: Jun 2022 --> Dec 2022
    Trial completion date • Trial primary completion date • Combination therapy
    |
    IFNG (Interferon, gamma)
    |
    temozolomide • Libtayo (cemiplimab-rwlc) • INO-5401 • rocakinogene sifuplasmid (INO-9012)
    almost2years
    Targeted Therapy for Adrenocortical Carcinoma: A Genomic-Based Search for Available and Emerging Options. (PubMed, Cancers (Basel))
    We identified TP53-modulating drugs to be possibly effective in 20-26% of patients, followed by the Wnt signaling pathway inhibitors (15%), Telomelysin and INO5401 (13%), FHD-609 (13%), etc. According to our data, 67% of ACC patients exhibited genomic alterations that might be targeted by FDA-approved drugs or drugs being tested in current clinical trials. Although there are not many current therapy options directly targeting reported ACC alterations, this study identifies emerging options that could be tested in clinical trials.
    Journal
    |
    TP53 (Tumor protein P53) • CDK4 (Cyclin-dependent kinase 4) • CTNNB1 (Catenin (cadherin-associated protein), beta 1) • FLT4 (Fms-related tyrosine kinase 4)
    |
    INO-5401 • FHD-609 • Telomelysin (suratadenoturev)
    2years
    WT1: The Hinge Between Anemia Correction and Cancer Development in Chronic Kidney Disease. (PubMed, Front Cell Dev Biol)
    We aimed to reveal the research gaps and offer a focused strategy to monitor the development and progression of specific types of cancer when using HIF-PHIs to treat anemia in CKD patients. In addition, to facilitate the long-term use of HIF-PHIs in anemic CKD patients, we will discuss the strategy of WT1 inhibition to reduce the development and progression of cancer.
    Review • Journal
    |
    WT1 (WT1 Transcription Factor)